Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H22FN3O |
| Molecular Weight | 339.4066 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1C[C@@H]1CN2C(C)=C(C)C3=C2C(OCC4=CC=C(F)C=C4)=NN=C3
InChI
InChIKey=NXPLYKRKIFPEOA-BLLLJJGKSA-N
InChI=1S/C20H22FN3O/c1-12-8-16(12)10-24-14(3)13(2)18-9-22-23-20(19(18)24)25-11-15-4-6-17(21)7-5-15/h4-7,9,12,16H,8,10-11H2,1-3H3/t12-,16+/m0/s1
| Molecular Formula | C20H22FN3O |
| Molecular Weight | 339.4066 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacodynamic and pharmacokinetic evaluation of CS-526 in cynomolgus monkeys. | 2009-12 |
|
| The effect of subchronic administration of 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methylcyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526), a novel acid pump antagonist, on gastric acid secretion and gastrin levels in rats. | 2008-07 |
|
| Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526). | 2007-10 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:27:04 GMT 2025
by
admin
on
Mon Mar 31 18:27:04 GMT 2025
|
| Record UNII |
K82NW38NLW
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9833312
Created by
admin on Mon Mar 31 18:27:04 GMT 2025 , Edited by admin on Mon Mar 31 18:27:04 GMT 2025
|
PRIMARY | |||
|
313272-12-7
Created by
admin on Mon Mar 31 18:27:04 GMT 2025 , Edited by admin on Mon Mar 31 18:27:04 GMT 2025
|
PRIMARY | |||
|
K82NW38NLW
Created by
admin on Mon Mar 31 18:27:04 GMT 2025 , Edited by admin on Mon Mar 31 18:27:04 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Antiulcer, Gastrokinetic; Mechanism of Action: Potassium-competitive acid blocker; Highest Development Phase: Discontinued for Gastro-oesophageal reflux and Peptic ulcer; Most Recent Event: 10 Oct 2003 Phase-I clinical trials in Gastro-oesophageal reflux in USA (PO)
|
